MicroPort Scientific Corporation

Robocath and MicroPort, through its subsidiary MedBot, finalized a joint venture to commercialize Robocath's R-One robotic-assisted platform in China. Robocath holds 49% and MedBot 51% of the joint venture.

MicroPort Scientific Corporation, through its Indian subsidiary, completed a $10 million strategic investment in Purple Medical Solutions, forming a joint venture focused on cardiovascular devices. MicroPort holds 32% initially, with plans to increase to 45%.

MicroPort Scientific led a strategic investment of SGD 8 million in NDR Medical, committing SGD 6 million for about 20.9% equity, and established a joint venture with NDR and Shanghai Youlong to commercialize puncture navigation robotic systems in Greater China.

MicroPort Scientific Corporation led a strategic investment of up to €40 million in Robocath and signed a binding term sheet to form a China-based joint venture for vascular robotics.

MicroPort Scientific Corporation, through its subsidiary Endovascular Technology Corporation, acquired the shares of Lombard Medical Limited and Lombard Medical Technologies GmbH in a restructuring under UK bankruptcy law. Lombard Medical, Inc. will be liquidated.

MicroPort Scientific Corporation and Chinese PE firm Yunfeng Capital will acquire the cardiac rhythm management (CRM) business of LivaNova for $190 million in cash.

LivaNova closed the $225 million acquisition of ImThera Medical, which makes the Aura6000 implantable hypoglossal nerve stimulator for sleep apnea. LivaNova paid $78 million upfront, with $147 million due on milestones.

LivaNova PLC and MicroPort Scientific Corporation announced that their Shanghai-based joint venture MicroPort Sorin Cardiac Rhythm Management Co. Ltd. obtained approval from the China Food and Drug Administration for its family of Rega pacemakers, the first domestically manufactured pacemakers in China meeting international standards.

Lombard Medical Technologies finalized a strategic partnership with MicroPort Scientific. MicroPort will manufacture components for Lombard's Aorfix and Altura devices in Shanghai and gain exclusive marketing rights in China and Brazil.

MicroPort Scientific Corporation's Indian subsidiary won its first hospital admission approval contract for the Firehawk coronary stent at a public hospital in India. The contract is valid for one year.

Lombard Medical and MicroPort Scientific Corporation announced a strategic partnership and $15 million investment by MicroPort, including exclusive marketing rights for Aorfix and Altura stent grafts in China and Brazil, and a component supply agreement.